Saturday, January 31, 2009
Genetic classification of ovarian carcinoma based on microsatellite analysis: Relationship to clinicopathological features and patient survival
abstract:
Genetic classification of ovarian carcinoma based on microsatellite analysis: Relationship to clinicopathological features and patient survival
These findings suggest that some ovarian carcinomas have a significant degree of overlap between the two pathways of genomic instability and that the genetic classification using microsatellite markers may represent a potential new biomarker of risk prediction in ovarian carcinoma.
Distribution of microsatellite instability in Danish ovarian tumor patients and the prognositic value in ovarian cancer patients
Distribution of microsatellite instability in Dani...[Oncol Res. 2008] - PubMed Result
In conclusion, we found no association to any of the clinical parameters evaluated, although a tendency of a higher frequency of MSI was observed among serous OC.
Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology
abstract:
Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology -- Pal et al. 14 (21): 6847 -- C
The frequency of the MSI-H phenotype in unselected ovarian cancers approximates 12%. MMR-deficient ovarian cancers also seem to be characterized by an overrepresentation of nonserous histologic subtypes. Knowledge of histologic subtype may aid clinicians in identifying the relatively large proportion of ovarian cancers due to MMR defects; such knowledge has potential implications for medical management.
Friday, January 30, 2009
Thursday, January 29, 2009
news article: Self-diagnosis can be risky - Dee Williams/ACOR ovarian listserv
Self-diagnosis can be risky | courier-journal | The Courier-Journal
"And she's found camaraderie by connecting with other ovarian cancer patients through such sites as The Association of Cancer Online Resources.
'The ovarian list is very active,' she said. 'Every day there's probably at least 50-60 posts. Someone will say, 'Hey, I'm starting this chemo treatment. What can you tell me about it?' and women will reply, 'Oh, I've been on it and it made me sick,' or 'It gave me diarrhea.' '
Women from inside and outside the United States participate, sometimes sharing journal articles and recommending doctors to each other, in addition to offering support, Edwards said.
Thanks to them, she said, 'I feel like I have a local support group and then I have my global support group' on the Internet."
Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence
Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence -- Mandelblatt and Silliman 27
Editorial:
"Aside from the acknowledged methodological caveats and the potentially misleading press surrounding the article by Badgwell et al,5 the study's investigators and the Journal of Clinical Oncology are to be commended for raising difficult questions in gero-oncology, especially when the answers are imperfect. The intensity about the controversy that followed this publication reflects the fact that we are ill-prepared from a scientific knowledge perspective to provide health care rationally, ethically, equitably, and humanely to the 'booming' older population."
When Informed, All Women Do Not Prefer Breast Conservation
When Informed, All Women Do Not Prefer Breast Conservation -- Throckmorton and Esserman 27 (4): 484 -- Journal of Clinical Oncology
The key to offering a choice is respecting the choices patients make. Some people will choose one path, others a different one. We need to accept that women will have different values and want different choices. Our job should be to make sure patients have the choices, the information, the time, and environment in which to make an informed, value-driven decision.
Should patient-rated performance status affect treatment decisions - ECOG score
PS=performance status
Should patient-rated performance status affect tre...[J Thorac Oncol. 2008] - PubMed Result
"CONCLUSIONS: Pt-PS and MD-PS were not congruent in over half of the cases, with Pt-PS scores usually poorer. Almost half the patients would have excluded themselves from a hypothetical clinical trial (Pt-PS >/=2). This requires prospective evaluation."
Wednesday, January 28, 2009
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
note: Table 4 does not include self image etc in gyn cancers but does in breast cancer
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers -- Rebbeck et al. 101 (2): 80 -- JNCI Journal of the National Cancer
Tuesday, January 27, 2009
Monday, January 26, 2009
HE4 Test with CA125 for Risk Stratification of Women with Suspected Ovarian Cancer
Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
ZAIDA - Caring Bridge journal
(Posted with permission of Mom): Zaida (ZAY-da) turned 4 in September. We learned she has cancer on 10/31/07, after six very emotional days in the hospital. Two days later we learned it was ovarian cancer. More recently, the diagnosis is mesothelioma of the peritoneum, with an ovarian promotor.
Older Patients and the Shifting Focus of Cancer Care
Older Patients and the Shifting Focus of Cancer Care - Cancer Network
"Conclusions
Society has treated elderly cancer patients poorly, even in cases where curative therapy exists."
Sunday, January 25, 2009
Diversity of participants in clinical trials in an academic medical center
Wiley InterScience :: JOURNALS :: Cancer
Further research also should consider whether differentially recruiting
good patients
can impact the ethnic/racial diversity or other characteristics of trial participants in ways that may bias the outcomes or conclusions of therapeutic trials.
Friday, January 23, 2009
webcast presentation: Menopause and Osteoporosis | January 22, 2009 | Media Advisories | Media Centre | SOGC
Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life - Italian mortality follow-back survey
Annals of Oncology Advance Access published online on January 22, 2009
Annals of Oncology, doi:10.1093/annonc/mdn700
| |
Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey
1 Regional Palliative Care Network, National Cancer Research Institute, Genoa
2 Palliative Care Unit, IRCCS Foundation, National Cancer Institute, Milan
3 Department of Epidemiology, National Cancer Research Institute, G. Pascale Foundation, Naples
4 ASP Lazio, Rome
5 Liguria Cancer Registry, Descriptive Epidemiology, National Cancer Research Institute, Genoa
6 Clinical Epidemiology, Center for the Study and Prevention of Cancer, Florence, Italy
* Correspondence to: Dr M. Costantini, Regional Palliative Care Network, National Cancer Research Institute, Largo R. Benzi, 10 16132 Genova, Italy. Tel: +39-010-5737482; Fax: +39-010-354103; E-mail: massimo.costantini@istge.it
Background: This study estimates prevalence, management, and relief of pain during the last 3 months of life of a representative sample of dying cancer patients in Italy.
Patients and methods: This is a mortality followback survey (the Italian Survey of the Dying of Cancer). Caregivers were interviewed, after the patient's death, about pain experienced by the patients in all settings of care.
Results: According to caregivers' reports, 82.3% [95% confidence interval (CI) 79.9% to 84.4%] patients experienced pain, and 61.0% (95% CI 57.9% to 64.0%) very distressing pain. The younger population experienced a higher prevalence of pain in respect to older patients (P <> central nervous system experienced the lowest prevalence (51.9%). According to caregivers' reports, only 59.5% (95% CI 3.7% to 65.0%) received analgesic treatment with opioids for moderate to severe pain. Not surprisingly, pain was ‘only partially relieved’ or ‘not relieved at all’ in 54% of the patients with very distressing pain.
Conclusions: Although potentially slightly biased, the results from this survey regarding undermedication and poor treatment results for cancer related pain are unequivocal. The research agenda should focus on testing the effectiveness of interventions to improve the quality of pain assessment and management.
cancer, effectiveness, opioids, pain, prevalence, treatment
Received for publication March 25, 2008. Revision received August 1, 2008. Accepted for publication October 7, 2008.
Thursday, January 22, 2009
Canada NewsWire Group
Canada NewsWire Group: "The webcast will explain key findings from the clinical review, with a focus on hormone therapy, osteoporosis, cardiac health and cognitive function.'"
The effect of obesity on survival in patients with ovarian cancer
Conclusion
Although obesity has been reported as an independent prognostic factor for survival, this data demonstrates that survival rates are similar between obese and non-obese patients when optimal debulking statuses are the same. Therefore, maximal effort should be directed towards optimal debulking obese patients with EOC.
Wednesday, January 21, 2009
Tuesday, January 20, 2009
Monday, January 19, 2009
Information exchange between provider and patient -- Brown 180 (2): 207 -- Canadian Medical Association Journal
Information exchange between provider and patient -- Brown 180 (2): 207 -- Canadian Medical Association Journal
"Emerging technologies such as patient-accessible electronic health records should be considered as a means of facilitating the transmission of information not only between providers but also between provider and patient to address gaps in the continuity of care."
CDC Issues Cancer Genetic Test Recommendations | GenomeWeb
CDC Issues Cancer Genetic Test Recommendations | GenomeWeb
"After conducting an evidence-based analysis, the CDC's Evaluation of Genomic Applications in Practice and Prevention Working Group, or EWG, said it could recommend offering genetic testing for Lynch syndrome to newly diagnosed colorectal cancer patients, but that it did not find enough evidence to recommend for or against two other types of genetic tests, for breast cancer and metastatic colorectal cancer."
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers -- Rebbeck et al., 10.1093/jnci/djn442 -- JNCI Journal of the National
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers -- Rebbeck et al., 10.1093/jnci/djn442 -- JNCI Journal of the National
In conclusion, the summary risk reduction estimates presented here confirm that BRCA1/2 mutation carriers who have been treated with RRSO have a substantially reduced risk of both breast and ovarian cancer. However, residual cancer risk remains after surgery. Therefore, additional cancer risk reduction and screening strategies are required to maximally reduce cancer incidence and mortality in this high-risk population.
Subscribe to:
Posts
(
Atom
)
